Close
Novotech
Jabsco PureFlo 21 Single Use

Press Releases

SMi present the 13th annual event – Advances and Progress in Drug Design

SPONSORED BY CHEMICAL COMPUTING GROUPSMi are proud to present the 13th annual Advances and Progress in Drug Design conference, convening in Central London on Monday 17 and Tuesday 18 February 2014. This exciting event will focus on new approaches...

Agilent Technologies and Seoul National University Hospital Collaborate on Biomarker Research

Agilent Technologies Inc. and Seoul National University Hospital one of Korea’s top medical centers today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs including narcotics immune-suppressants and biomarkers. ...

Nosopharm receives EUR 870,000 (USD 1.18 million) to help combat antibiotic resistance

Nosopharm specializes in the research and development of new anti-infective drugs, today announces that it has secured funding of EUR 870,000 (USD 1.18 million). The company is receiving this funding as part of the OOPERA...

Secukinumab showed superiority over Enbrel®

Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab an interleukin-17A inhibitor, was significantly superior to Enbrel in moderate-to-severe plaque psoriasis. Enbrel is a current standard-of-care anti-TNF medication approved to treat moderate-to-severe plaque...

2013 Utah Life Science Summit Features Top State and National Leaders, Unrivalled Networking Opportunities

BioUtah today released the agenda for the 2013 Utah Life Science Summit Utah’s premier life science event which will be held all day November 6 at the Grand America Hotel in Salt Lake City Utah. ...

Lannett Announces Proposed Public Offering of Common Stock

Lannett Company Inc. today announced that it and certain selling stockholders intend to offer shares of the Company’s common stock in an underwritten public offering. The proposed offering is subject to market and other conditions...

Cancer Vaccine Company DCPrime and Janssen To Collaborate on Potential New Therapy

Cancer vaccine company DCPrime BV today announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals Inc. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Centre where a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »